MISSION Therapeutics
Biotechnology company developing therapies that enhance mitophagy (removal of dysfunctional mitochondria) to combat serious diseases including neurodegeneration and cancer.
Location
Cambridge, United Kingdom
Founded
2011
Investors
1
Categories
biotech, mitochondria, therapeutics, neurodegeneration, dub-inhibitors
Notes
MISSION Therapeutics is a biotechnology company pioneering the development of deubiquitylase (DUB) inhibitors to enhance mitophagy—the selective removal of damaged or dysfunctional mitochondria. Mitochondrial dysfunction is implicated in numerous serious diseases, including Parkinson's disease, other neurodegenerative conditions, and certain cancers.
Based in Cambridge, UK, MISSION is developing first-in-class small molecule drugs that target specific DUBs to restore healthy mitochondrial function and cellular homeostasis.
Team
- Anker Lundemose, M.D., Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/ankerlundemose
Additional Research Findings
- Founded in 2011
- Headquarters in Cambridge, United Kingdom
- Portfolio company of Sofinnova Partners
- Focus on DUB inhibitors for mitophagy enhancement
- Lead programs in neurodegeneration
- Disease-modifying approach to Parkinson's disease
- First-in-class small molecule therapeutics
- Cambridge biotech cluster
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |